Natural killer cell therapy shows powerful anti-tumour activity
Gamida Cell has revealed early data in 10 patients with CD20 positive non-Hodgkin lymphoma as part of an ongoing study of natural killer (NK) cell therapy candidate GDA-201. The multicentre Phase I study is designed to evaluate safety and determine the maximum tolerated dose. Read More